Cas No.: | 2241664-16-2 |
Chemical Name: | JNJ4796 |
Synonyms: | JNJ4796;N-[2-(2-{4-[(R)-(2-methyl-2H-tetrazol-5-yl)(phenyl)methyl]piperazine-1-carbonyl}pyridin-4-yl)-1,3-benzoxazol-5-yl]acetamide;EZ7;Q62019796;(R)-N-(2-(2-(4-((2-methyl-2H-tetrazol-5-yl)(phenyl)methyl)piperazine-1-carbonyl)pyridin-4-yl)benzo[d]oxazol-5-yl)acetamide;N-[2-[2-[4-[(R)-(2-Methyltetrazol-5-yl)-phenylmethyl]piperazine-1-carbonyl]pyridin-4-yl]-1,3-benzoxa |
SMILES: | O=C(C1C=C(C2=NC3C=C(C=CC=3O2)NC(C)=O)C=CN=1)N1CCN([C@@H](C2N=NN(C)N=2)C2C=CC=CC=2)CC1 |
Formula: | C28H27N9O3 |
M.Wt: | 537.572484254837 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | JNJ4796 (JNJ 4796, JNJ-4796) is an orally active small-molecule fusion inhibitor of influenza virus hemagglutinin (HA) with EC50 of 33 nM (H1N1 neutralization); mimics the binding and functionality of the broadly neutralizing antibody CR6261; targets the conserved HA stem region, acts as a fusion inhibitor by inhibiting conformational changes that lead to the postfusion HA structure, and neutralizes a broad spectrum of human pandemic, seasonal, and emerging group 1 influenza A viruses; specificly neutralizes influenza A group 1 viruses by inhibiting HA-mediated fusion in vitro, protects mice against lethal and sublethal influenza challenge after oral administration. |